Biotechnology

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

A mining firm just secured a key gene therapy patent for ALS. Timothy Bell dissects the audacious strategy of funding cutting-edge biotech with Greenland's mineral wealth.

Kraig Biocraft Labs is turning the mythical strength of spider silk into a commercial reality. But can its maverick CEO and record-setting production overcome the financial hurdles?

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

The biotech's complex warrant restructuring is more than a balance sheet clean-up; it's a strategic masterstroke paving the way for its MASH drug.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Amplia Therapeutics' new patent application for novel FAK inhibitors extends protection to 2046, signaling a major play in oncology and fibrosis markets.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

A biotech firm just printed kidney and liver tissue in space for the first time, proving orbital manufacturing isn't science fiction, but our medical future.

A biotech's preclinical success in treating miscarriage is just the start. The real story is its strategy of using pregnancy immunology to target cancer.

As Immunic executives meet investors, the real audience is the future. With pivotal data on its MS drug due this year, the firm is navigating a high-risk path.

Foresee Pharmaceuticals signals a major shift to commercialization, appointing Brian J. Groch to lead the launch of its 6-month CPP treatment, FP-001.

With a landmark NEJM publication and FDA approval, Rhythm Pharma's setmelanotide offers hope for a rare obesity, proving a potent strategy for niche markets.

Millions suffer through frequent eye injections for wet AMD. A new partnership aims to change that with a targeted drug and microneedle system, promising a precision strike at the disease's core.

With a multi-million-dollar Series B, Kuehnle AgroSystems is commercializing a novel tech that promises to upend the $2B natural astaxanthin market.

Ultragenyx bets 62% of its budget on R&D while unprofitable. Its new Impact Report reveals a strategy where patient access and ESG are the real assets.